Репозиторий Университета

© 2018 Limited Liability Company KlinMed Consulting. All Rights Reserved. The article describes the definition of dementia, its diagnostic criteria, classification. Differences in the pathogenesis and clinical manifestations of different types of dementia are considered. The issues of interrelation of arterial hypertension and the risk of development of cognitive disorders and dementia in old and very old people are discussed in detail. Data on the effect of antihypertensive drugs of different groups on the risk of dementia and the state of cognitive functions are presented. The evidence base of dihydropyridine calcium antagonist amlodipine and thiazide-like diuretic indapamide-retard is discussed with respect to the prevention of dementia and cognitive decline and their beneficial effect on cognitive function in patients with arterial hypertension.

© 2018 Vserossiiskoe Obshchestvo Kardiologov. All rights reserved. The article is focused on a broad evidence of antihypertension efficacy of perindopril and bisoprolol. The issues considered, of the drugs usage in patients with arterial hypertension, ischemic heart disease and chronic heart failure according to the international and local clinical guidelines. Special attention is paid for the influence of perindopril and bisoprolol on prognosis - the risk of cardiovascular complications from the evidence based medicine perspective. The data provided on a novel unique combination of these medications, and the benefits are accounted, as the mechanism of complimentary interaction; the results of randomized trials, clinical trials provided, that point on the high potential of this sort of combinational treatment.

© Team of authors, 2018. Objective. To investigate the efficacy of divaza in outpatients with cognitive disorders and chronic brain ischemia (CBI). Material and methods. The non-interventional observational program included the data of 2583 outpatients with CBI from 30 cities (8 federal okrugs of the Russian Federation) who were on outpatient neurological treatment and received divaza in a dose of 2 tablets three times a day from Oct 2016 to Jan 2017. Cognitive functions were evaluated using the MoCA scale before and after 3 months of treatment. Results and conclusion. Cognitive disorders were identified in 90.7% of patients (<26 МоСА scores). After treatment, the mean MoCA score increased from 19.58 ± 5.13 to 23.99 ± 4.21 (p<0.0001), the number of patients with normal cognitive functions rate (≥26 scores) increased from 9.3 to 41.3%, the number of patients with marked cognitive impairment decreased. The drug was well-tolerated by old and very old patients, adverse events were observed rarely (0.6% of cases). The majority of doctors (88.4%) noticed the effect of divaza as significant improvement or improvement, and 89.6% of patients valued the effect to be excellent or good. The use of divaza, the drug with endothelioprotective and nootropic effects, is pathogenetically justified and promising in patients with cognitive disorders of vascular etiology.

© 2018 Russian Association of Endocrinologists. All rights reserved. The presented paper is a third revision of the clinical recommendations for the treatment of morbid obesity in adults. Morbid obesity is a condition with body mass index (BMI) ≥40 kg / m2 or a BMI ≥35 kg / m2 in the presence of serious complications associated with obesity. The recommendations provide data on the prevalence of obesity, its etiology and pathogenesis, as well as on associated complications. The necessary methods for laboratory and instrumental diagnosis of obesity are described in detail. In this revision of the recommendations, the staging of prescribing conservative and surgical methods for the treatment of obesity are determined. For the first time, a group of patients with obesity and type 2 diabetes mellitus is selected, in whom metabolic surgery allows a long-term improvement in the control of glycemia or remission of diabetes mellitus.

Повышение активности ренин-ангиотензин-альдостероновой системы - один из важнейших механизмов реализации сердечно-сосудистого континуума. Рассматривается роль, которую блокаторы рецепторов ангиотензина играют в достижении целевых цифр артериального давления и снижении сердечно-сосудистого риска. Освещается значение плейотропных свойств блокаторов рецепторов ангиотензина (в частности, активации гамма рецепторов, активируемых пероксисомными пролифераторами - PPAR-y) в ведении больных с инсулинорезистентностью, ожирением, дислипидемией. Обсуждается доказательная база применения телмисартана как препарата, обладающего плейотропным действием, у больных с артериальной гипертензией и сочетанными заболеваниями (сахарный диабет, ожирение, нарушение функции почек).

Повышение активности ренин-ангиотензин-альдостероновой системы - один из важнейших механизмов реализации сердечно-сосудистого континуума. Рассматривается роль, которую блокаторы рецепторов ангиотензина играют в достижении целевых цифр артериального давления и снижении сердечно-сосудистого риска. Освещается значение плейотропных свойств блокаторов рецепторов ангиотензина (в частности, активации гамма рецепторов, активируемых пероксисомными пролифераторами - PPAR-y) в ведении больных с инсулинорезистентностью, ожирением, дислипидемией. Обсуждается доказательная база применения телмисартана как препарата, обладающего плейотропным действием, у больных с артериальной гипертензией и сочетанными заболеваниями (сахарный диабет, ожирение, нарушение функции почек).